What were Kwality Pharmaceuticals Ltd's latest quarterly results?
Kwality Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +77.8% (stable)
- Revenue Growth YoY: +46.4%
- Operating Margin: 24.0% (expanding)
Kwality Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +52.6%Strong6w StreakRe-Entry
In , Kwality Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +52.6% relative strength. Fundamentals: Strong. On a 6-week streak.
Kwality Pharmaceuticals Ltd Key Facts
- PE Ratio
- 31.7x
- Market Cap
- ₹1,809 Cr
- PAT Growth YoY
- +78%
- Revenue Growth YoY
- +46%
- OPM
- 24.0%
- RS vs Nifty 500
- +52.6%
PE: At PeakRiding Wave
What's Happening
📊PE near cycle highs — limited room for further expansion
Key Numbers
PAT Growth YoY
+78%
Stable
Revenue YoY
+46%
Stable
Operating Margin
24.0%
+300 bps YoY
PE Ratio
31.7
Current Price
₹1,744
Fundamental Score
62/100
Strong
3Y PAT CAGR
-31%
Market Cap
1.8K Cr
Valuation
Slightly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Kwality Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +46% | -7% | Stable |
| PAT (Net Profit) | +78% | -31% | Stable |
| OPM | 24.0% | +300 bps | Expanding |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Kwality Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Kwality Pharmaceuticals Ltd's profit growing or declining?
Kwality Pharmaceuticals Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +77.8% (latest quarter)
- PAT Growth QoQ: +14.3% (sequential)
- 3-Year PAT CAGR: -30.7%
- Trend: Stable — consistent growth pattern
What is Kwality Pharmaceuticals Ltd's revenue growth trend?
Kwality Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +46.4%
- Revenue Growth QoQ: +10.8% (sequential)
- 3-Year Revenue CAGR: -6.7%
How is Kwality Pharmaceuticals Ltd's operating margin trending?
Kwality Pharmaceuticals Ltd's operating margin is expanding.
- Current OPM: 24.0%
- OPM Change YoY: +3.0% basis points
- OPM Change QoQ: +1.0% basis points
What is Kwality Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Kwality Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: -30.7%
- 3-Year Revenue CAGR: -6.7%
Is Kwality Pharmaceuticals Ltd's growth accelerating or decelerating?
Kwality Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: +2.8% bps
- Sequential Acceleration: -2.4% bps
What is Kwality Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Kwality Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹56 Cr
- TTM PAT Growth: +93.1% YoY
- TTM Revenue: ₹461 Cr
- TTM Revenue Growth: +33.2% YoY
- TTM Operating Margin: 22.8%
Is Kwality Pharmaceuticals Ltd overvalued or undervalued?
Kwality Pharmaceuticals Ltd appears slightly undervalued based on our fair value analysis.
- Valuation Signal: Slightly Undervalued
- Current PE: 31.7x
- Price-to-Book: 6.2x
What is Kwality Pharmaceuticals Ltd's current PE ratio?
Kwality Pharmaceuticals Ltd's current PE ratio is 31.7x.
- Current PE: 31.7x
- Market Cap: 1.8K Cr
How does Kwality Pharmaceuticals Ltd's valuation compare to its history?
Kwality Pharmaceuticals Ltd's current PE is 31.7x.
- Current PE: 31.7x
- Valuation Assessment: Slightly Undervalued
What is Kwality Pharmaceuticals Ltd's price-to-book ratio?
Kwality Pharmaceuticals Ltd's price-to-book ratio is 6.2x.
- Price-to-Book (P/B): 6.2x
- Book Value per Share: ₹280
- Current Price: ₹1744
Is Kwality Pharmaceuticals Ltd a fundamentally strong company?
Kwality Pharmaceuticals Ltd is rated Strong with a fundamental score of 62.3/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +46.4% (10% weight)
- PAT Growth YoY: +77.8% (10% weight)
- PAT Growth QoQ: +14.3% (10% weight)
- Margins expanding (10% weight)
Is Kwality Pharmaceuticals Ltd debt free?
Kwality Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹110 Cr
What is Kwality Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Kwality Pharmaceuticals Ltd's return ratios over recent years
- FY2023: ROCE 19.0%
- FY2024: ROCE 16.0%
- FY2025: ROCE 18.0%
Is Kwality Pharmaceuticals Ltd's cash flow positive?
Kwality Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹53 Cr
- Free Cash Flow (FCF): ₹24 Cr
- CFO/PAT Ratio: 133% (strong cash conversion)
What is Kwality Pharmaceuticals Ltd's dividend yield?
Kwality Pharmaceuticals Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹1744
Who holds Kwality Pharmaceuticals Ltd shares — promoters, FII, DII?
Kwality Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 54.9%
- FII (Foreign): 2.8%
- DII (Domestic): 0.4%
- Public: 42.0%
Is promoter holding increasing or decreasing in Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's promoter holding has increased recently.
- Current Promoter Holding: 54.9% (Mar 2026)
- Previous Quarter: 54.8% (Dec 2025)
- Change: +0.05% (increasing — positive signal)
How long has Kwality Pharmaceuticals Ltd been outperforming Nifty 500?
Kwality Pharmaceuticals Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Is Kwality Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Kwality Pharmaceuticals Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
Is Kwality Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Kwality Pharmaceuticals Ltd may be worth studying
- Earnings growing at +77.8% YoY
- Operating margins are expanding — OPM at 24.0%
- Valuation: appears slightly undervalued
- Cash flow is positive — CFO ₹53 Cr
What is the investment thesis for Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +46.4% YoY
- Margins expanding
What is the future outlook for Kwality Pharmaceuticals Ltd?
Kwality Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: expanding
- Valuation: Slightly Undervalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.